Webcast/CME - Clinical Experience with Vorinostat in CTCL and Sézary Syndrome

	Unregistered User Click here if this is not your Personal Edition
		Contact Us \| Free E-Mail Updates \| Journals \| Register a colleague

Dermatology Other

EXPLORE :

Most Read News

All Webcasts / CME

Warning | Privacy

Recent webcasts/CME - Dermatology Other

	The Prevention and Treatment of Pressure Ulcers
	Contemporary Options for the Management of Scars
	Pediatric and Adolescent Sports-Related Injuries and Ailments
	Surgery: Current Challenges in Surgery: Complicated Skin and Soft Tissue Infections
	The Wound Healing Process

Recent news - Dermatology Other

	Topical Cream Effective Against Cetuximab-Induced Acne-Like Rash: Presented at ESMO-GI - (DGDispatch)
	Study Characterises Eczema Patients Most at Risk for Dangerous Viral Infections - (DGNews)
	Topical Fluorouracil Reduces Number of Actinic Keratoses, Improves Skin Damage - (DGNews)
	Actinic Keratoses Responsible for More Cancer Types Than Once Believed - (DGNews)
	Oral Linezolid as Effective as Intravenous Vancomycin in Treating MRSA in Complicated Skin and Soft Tissue Infections: Presented at ECCMID - (DGDispatch)

Recent cases - Dermatology Other

	A Patient with Prickling Boils
	Acute Generalized Exanthematous Pustulosis (AGEP) Triggered by a Spider Bite
	A 72-Year-Old Man with a Purpuric Rash
	The First Case of Isolated Facial Cutanenous Leishmaniasis in a Down Syndrome Infant: A Case Report and Review of the Literature
	Bullous Dermatosis

personal edition > dermatology other > webcasts/CME

Webcasts/CME

E-Mail this webcast/CME to a colleague

Clinical Experience with Vorinostat in CTCL and Sézary Syndrome

Presented by:	The University of Kentucky College of Medicine
Lecturer	Francine Foss, MD
Approximate duration:	Not available
Summary points:	This audiovisual presentation discusses the classifications of cutaneous T-cell lymphoma and Sézary syndrome, the epidemiology and aetiology of mycosis fungoides, disease-specific survival rates, clinical responses to various therapies and immunotherapy, treatment of advanced stage/refractory patients, data from the Depsipeptide Phase 2 study, and evidence from clinical trials of vorinostat, known drug-related adverse effects.
Accreditation:	The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. The University of Kentucky College of Medicine designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credits. Expiration date: January 1, 2007.
Other:

Additional Information